Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
|Videos|October 19, 2017
Dr. Metz on Somatostatin Analogs and Emerging Agents in NETs Landscape
Author(s)David C. Metz, MD
David C. Metz, MD, PhD, associate chief for Clinical Affairs, Gastrointestinal Division, Penn Medicine, University of Pennsylvania, discusses the utility of somatostatin analogs and emerging agents in the landscape of neuroendocrine tumors (NETs).
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5